Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients (EnligHTN-I)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Catheter-based renal artery ablation, Hypertension, Resistant to Conventional Therapy
Eligibility Criteria
Inclusion Criteria:
- Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior to enrollment
- Age ≥18 and ≤80 years old
- Able and willing to provide written informed consent to participate in the study
- Able and willing to comply with the required follow-up schedule
Exclusion Criteria:
- Prior renal artery intervention (balloon angioplasty or stenting)
- Evidence of renal artery atherosclerosis (defined as a stenotic severity of >30%) in either renal artery
- Multiple main renal arteries in either kidney
- Main renal arteries <4 mm in diameter or <20 mm in length
- eGFR of <45 mL/min per 1.73 m2 using the MDRD formula
- Type 1 diabetes
- Renovascular hypertension or hypertension secondary to other renal disorders (glomerulonephritis, polycystic kidney disease, end-stage renal failure)
- Others
Sites / Locations
- Royal Adelaide Hospital
- Flinders Medical Centre
- Monash Medical Centre
- Hippokration Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
renal artery ablation
Arm Description
Catheter-based RF ablation in renal artery
Outcomes
Primary Outcome Measures
Adverse Events
All device or procedure related adverse events
Office Systolic Blood Pressure Change
Secondary Outcome Measures
Full Information
NCT ID
NCT01438229
First Posted
September 19, 2011
Last Updated
February 1, 2019
Sponsor
Abbott Medical Devices
1. Study Identification
Unique Protocol Identification Number
NCT01438229
Brief Title
Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
Acronym
EnligHTN-I
Official Title
Ablation-induced Renal Sympathetic Denervation Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
July 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Abbott Medical Devices
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a prospective, multicenter, feasibility study on the safety and efficacy of renal denervation in patients with resistant hypertension.
Detailed Description
Demonstrate the safety and efficacy of the St. Jude Medical Radiofrequency (RF) Renal Denervation System in the treatment of patients with resistant hypertension.
Safety Marker
All adverse events
Efficacy Marker
Office blood pressure
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Catheter-based renal artery ablation, Hypertension, Resistant to Conventional Therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
47 (Actual)
8. Arms, Groups, and Interventions
Arm Title
renal artery ablation
Arm Type
Experimental
Arm Description
Catheter-based RF ablation in renal artery
Intervention Type
Device
Intervention Name(s)
St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
Intervention Description
Catheter-based RF ablation in renal artery
Primary Outcome Measure Information:
Title
Adverse Events
Description
All device or procedure related adverse events
Time Frame
24 months
Title
Office Systolic Blood Pressure Change
Time Frame
Baseline to 6 months
Other Pre-specified Outcome Measures:
Title
Office Diastolic BP Change
Time Frame
Baseline to 6M
Title
Office Systolic BP Change
Time Frame
Baseline to 12M
Title
Office Systolic BP Change
Time Frame
Baseline to 18 months
Title
Office Systolic BP Change
Time Frame
Baseline to 24 months
Title
Office Diastolic BP Change
Time Frame
Baseline to 12 months
Title
Office Diastolic BP Change
Time Frame
Baseline to 18 months
Title
Office Diastolic BP Change
Time Frame
Baseline to 24 months
Title
24hr Ambulatory Systolic BP Change
Description
Average of readings taken every half hour during the course of a 24hr period wearing the ambulatory blood pressure monitor. Includes only subjects who completed the test at both baseline and follow up. If a subject refused to wear the monitor they were excluded.
Time Frame
Baseline to 6 months
Title
24hr Ambulatory Systolic BP Change
Description
Average of readings taken every half hour during the course of a 24hr period wearing the ambulatory blood pressure monitor. Includes only subjects who completed the test at both baseline and follow up. If a subject refused to wear the monitor they were excluded.
Time Frame
Baseline to 12 months
Title
24hr Ambulatory Systolic BP Change
Description
Average of readings taken every half hour during the course of a 24hr period wearing the ambulatory blood pressure monitor. Includes only subjects who completed the test at both baseline and follow up. If a subject refused to wear the monitor they were excluded.
Time Frame
Baseline to 24 months
Title
24hr Ambulatory Diastolic BP Change
Description
Average of readings taken every half hour during the course of a 24hr period wearing the ambulatory blood pressure monitor. Includes only subjects who completed the test at both baseline and follow up. If a subject refused to wear the monitor they were excluded.
Time Frame
Baseline to 6 months
Title
24hr Ambulatory Diastolic BP Change
Description
Average of readings taken every half hour during the course of a 24hr period wearing the ambulatory blood pressure monitor. Includes only subjects who completed the test at both baseline and follow up. If a subject refused to wear the monitor they were excluded.
Time Frame
Baseline to 12 months
Title
24hr Ambulatory Diastolic BP Change
Description
Average of readings taken every half hour during the course of a 24hr period wearing the ambulatory blood pressure monitor. Includes only subjects who completed the test at both baseline and follow up. If a subject refused to wear the monitor they were excluded.
Time Frame
Baseline to 24 months
Title
Urine Albumin to Creatinine Ratio
Time Frame
Baseline
Title
Urine Albumin to Creatinine Ratio
Time Frame
6 months
Title
Urine Albumin to Creatinine Ratio
Time Frame
12 months
Title
Urine Albumin to Creatinine Ratio
Time Frame
18 months
Title
Urine Albumin to Creatinine Ratio
Time Frame
24 months
Title
Estimated Glomular Filtration Rate
Description
Calculated using Modifide Diet in Renal Disease formula.
estimated GFR = 186 x SerumCr-1.154 * age-0.203 * 1.212 (if patient is black) * 0.742 (if female)
Time Frame
Baseline
Title
Estimated Glomular Filtration Rate
Description
Calculated using Modifide Diet in Renal Disease formula.
estimated GFR = 186 x SerumCr-1.154 * age-0.203 * 1.212 (if patient is black) * 0.742 (if female)
Time Frame
6 months
Title
Estimated Glomular Filtration Rate
Description
Calculated using Modifide Diet in Renal Disease formula.
estimated GFR = 186 x SerumCr-1.154 * age-0.203 * 1.212 (if patient is black) * 0.742 (if female)
Time Frame
12 months
Title
Estimated Glomular Filtration Rate
Description
Calculated using Modifide Diet in Renal Disease formula.
estimated GFR = 186 x SerumCr-1.154 * age-0.203 * 1.212 (if patient is black) * 0.742 (if female)
Time Frame
18 months
Title
Estimated Glomular Filtration Rate
Description
Calculated using Modifide Diet in Renal Disease formula.
estimated GFR = 186 x SerumCr-1.154 * age-0.203 * 1.212 (if patient is black) * 0.742 (if female)
Time Frame
24 months
Title
Cystatin C
Time Frame
Baseline
Title
Cystatin C
Time Frame
6 months
Title
Cystatin C
Time Frame
12 months
Title
Cystatin C
Time Frame
18 months
Title
Cystatin C
Time Frame
24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Office systolic blood pressure that remains ≥160 mmHg (≥150 mmHg for patient with type 2 diabetes) despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic, for a minimum of 14 days prior to enrollment
Age ≥18 and ≤80 years old
Able and willing to provide written informed consent to participate in the study
Able and willing to comply with the required follow-up schedule
Exclusion Criteria:
Prior renal artery intervention (balloon angioplasty or stenting)
Evidence of renal artery atherosclerosis (defined as a stenotic severity of >30%) in either renal artery
Multiple main renal arteries in either kidney
Main renal arteries <4 mm in diameter or <20 mm in length
eGFR of <45 mL/min per 1.73 m2 using the MDRD formula
Type 1 diabetes
Renovascular hypertension or hypertension secondary to other renal disorders (glomerulonephritis, polycystic kidney disease, end-stage renal failure)
Others
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vasilias Papademetriou, MD
Organizational Affiliation
First Cardioligy Clinic, Hippokration Hospital, University of Athens, Greece
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Konstantinos Tsioufis, MD
Organizational Affiliation
First Cardioligy Clinic, Hippokration Hospital, University of Athens, Greece
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Stephen Worthley, MD
Organizational Affiliation
Cardiovascular Investigation Unit, Royal Adelaide Hospital, Adelaide, Australia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ian Meredith, MD
Organizational Affiliation
Monash Medical Centre, Melbourne, Australia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Derek Chew, MD
Organizational Affiliation
Flinders Medical Centre, Adelaide, AUSTRALIA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Adelaide Hospital
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5000
Country
Australia
Facility Name
Flinders Medical Centre
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Facility Name
Monash Medical Centre
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3168
Country
Australia
Facility Name
Hippokration Hospital
City
Athens
Country
Greece
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy Study of Renal Artery Ablation in Resistant Hypertension Patients
We'll reach out to this number within 24 hrs